For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).
New research at the University of Alberta may make it easier to diagnose serious diseases that disrupt the body's energy ...
UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...
As symptoms worsen, they often spread throughout ... thereby providing therapeutic effects for patients with severe myasthenia gravis mediated by autoantibodies. It received approval from the ...
Abby Smith, 40, a NHS manager from Reading, has the rare autoimmune disease myasthenia gravis, which means she needs her ...
The symptoms of myasthenia gravis can be very, very devastating. They can be life threatening. Why do people get myasthenia gravis? Autoantibody-driven diseases, and the wider autoimmunity space ...
Approval in Myasthenia gravis in key markets could eventually ... and continued to suffer from significant unresolved disease symptoms. These can include difficulties seeing, walking, talking ...
The UK regulatory authority has cleared the path for some patients with generalised myasthenia gravis (gMG ... struggle to manage the debilitating symptoms of this rare autoimmune disease." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback